ClinicalTrials.gg

Program

TQB2825

A development code. Also written as “TQB2825 injection +R-CHOP regimen”, “TQB2825 injection + GemOx” and “TQB2825 Injection”.

In Sino Biopharmaceutical's pipeline, CD20/CD3双抗. Its studies are mostly in Lymphoma, Large B-Cell, Diffuse · Lymphoma, Follicular · Hematologic Neoplasms, led by Sino Biopharmaceutical.

Furthest: phase 3, since Sep 17, 20255 company-led studies, 4 open or runningNext primary completion: Oct 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical54 open or runningphase 3since Sep 17, 2025Jun 17, 2022Oct 2028phase 3 · NCT07187960
  • Named in Sino Biopharmaceutical’s own pipeline as TQB2825, phase 3, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 17, 2022First study: phase 1 study in Hematologic NeoplasmsFirst studyNCT05489276 · 180 enrolled · China
  2. Feb 12, 20252 phase 2 studies in Lymphoma, Large B-Cell, DiffuseNCT06829771, NCT06854445
  3. Jul 31, 2025Phase 1 study in CD20-positive Hematological MalignanciesNCT07110194 · 75 planned · China
  4. Sep 17, 2025Phase 3 study in Lymphoma, FollicularNCT07187960 · 228 planned · China

Ahead

  1. Oct 2028Primary completion: phase 3 study in Lymphoma, FollicularNCT07187960

TargetBeta

“CD20/CD3双抗”the company's pipeline, read by Claude · source

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
mosunetuzumabruleHoffmann-La Rochephase 314
glofitamabruleHoffmann-La Rochephase 313
epcoritamabruleGenmabphase 313
odronextamabruleRegeneron Pharmaceuticalsphase 38
Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492AstraZenecaphase 22
GSK5926371GlaxoSmithKlinephase 22
REGN9220ruleRegeneron Pharmaceuticalsphase 21
Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543ruleJohnson & Johnsonphase 13

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07187960Lymphoma, Follicular · China3Not yet recruitingOct 2028228
NCT07110194CD20-positive Hematological Malignancies · China1Not yet recruitingMar 202675
NCT06854445Lymphoma, Large B-Cell, Diffuse · China2RecruitingOct 202555
NCT06829771Lymphoma, Large B-Cell, Diffuse · China2RecruitingMay 202690
NCT05489276Hematologic Neoplasms · China1UNKNOWNOct 2023180

How it is read

Names in the registry

  • “TQB2825 injection +R-CHOP regimen”, 1 entry
  • “TQB2825 injection + GemOx”, 1 entry
  • “TQB2825 Injection”, 1 entry
  • “TQB2825 Injection (Subcutaneous Injection)”, 1 entry
  • “TQB2825 Injection + Gemcitabine Hydrochloride for Injection + Oxaliplatin for Injection”, 1 entry

Codes read as this program: TQB2825.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.